[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Delcath Systems Inc (DCTH)

Delcath Systems Inc (DCTH)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Market News and Commentary

Can Delcath Systems Finally Justify a Valuation Built on Tomorrow's Revenue?

Delcath Systems Inc (DCTH) reports second-quarter 2026 earnings before market open on August 6, 2026, with analysts expecting a loss of $0.16 per share—a sharp reversal from the $0.07 profit posted in the same quarter last year. The central question for investors: can the company's HEPZATO KIT commercial momentum offset rising R&D and SG&A expenses as it scales operations and pursues new clinical programs? With the stock trading at $12.63 and analyst price targets implying significant upside, this report will test whether management's full-year guidance remains intact and whether the path to sustained profitability is on track.

Fundamentals

See More
  • Market Capitalization, $K 436,013
  • Shares Outstanding, K 34,522
  • Annual Sales, $ 85,230 K
  • Annual Income, $ 2,700 K
  • EBIT $ -2 M
  • EBITDA $ -3 M
  • 60-Month Beta 0.52
  • Price/Sales 5.32
  • Price/Cash Flow 249.45
  • Price/Book 3.99

Options Overview Details

View History
  • Implied Volatility 96.14% (+0.97%)
  • Historical Volatility 50.03%
  • IV Percentile 59%
  • IV Rank 20.80%
  • IV High 289.81% on 02/06/26
  • IV Low 45.27% on 08/21/25
  • Expected Move (DTE 15) 1.61 (12.72%)
  • Put/Call Vol Ratio 1.04
  • Today's Volume 137
  • Volume Avg (30-Day) 163
  • Put/Call OI Ratio 0.10
  • Today's Open Interest 4,426
  • Open Int (30-Day) 4,258
  • Expected Range 11.02 to 14.24

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 6 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/26
See More
  • Average Estimate $-0.16
  • Number of Estimates 1
  • High Estimate $-0.16
  • Low Estimate $-0.16
  • Prior Year $0.07
  • Growth Rate Est. (year over year) -328.57%

Price Performance

See More
Period Period Low Period High Performance
1-Month
11.50 +21.74%
on 07/29/26
14.00 unch
on 08/06/26
+0.52 (+3.86%)
since 07/06/26
3-Month
10.20 +37.25%
on 06/03/26
14.00 unch
on 08/06/26
+2.74 (+24.33%)
since 05/06/26
52-Week
8.12 +72.41%
on 11/20/25
14.00 unch
on 08/06/26
+3.36 (+31.58%)
since 08/06/25

Most Recent Stories

More News
Delcath Systems Reports Second Quarter 2026 Results and Business Highlights

Increases 2026 Revenue Guidance to a Range of $104M to $108M Conference Call Today at 8:30 a.m. Eastern Time

DCTH : 14.00 (+10.85%)
Can Delcath Systems Finally Justify a Valuation Built on Tomorrow's Revenue?

Barchart Research What to Expect from DCTH Earnings DCTH Generated August 5, 2026 Current Price $12.63 EPS Estimate $$-0.16 Consensus Rating Strong Buy Average Move 5.82% Can Delcath Systems Finally Justify...

DCTH : 14.00 (+10.85%)
Delcath Systems to Participate at the Canaccord Genuity 46th Annual Growth Conference

Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, today announced that management will be attending the Canaccord...

DCTH : 14.00 (+10.85%)
Delcath Systems to Host Second Quarter 2026 Earnings Call

Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announced today it will host a conference call on August...

DCTH : 14.00 (+10.85%)
Delcath Systems, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Delcath Systems, Inc. (Nasdaq: DCTH) (the “Company” or “Delcath”), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announces that the...

DCTH : 14.00 (+10.85%)
Delcath Systems Announces First Patient Dosed in Phase 2 Clinical Trial of HEPZATO™ in Liver-Dominant Metastatic Breast Cancer

Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic liver cancers, today announced that the first patient has been dosed at the European...

DCTH : 14.00 (+10.85%)
Delcath Systems Announces Two ASCO 2026 Investigator Initiated Trials-in-Progress Abstracts

Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, today announced the publication of two investigator-initiated...

DCTH : 14.00 (+10.85%)
Delcath Systems, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Delcath Systems, Inc. (Nasdaq: DCTH) (the “Company” or “Delcath”), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announces that the...

DCTH : 14.00 (+10.85%)
Delcath Systems to Participate at the H.C. Wainwright 4th Annual BioConnect Investor Conference

Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, today announced that management will be attending the H.C....

DCTH : 14.00 (+10.85%)
Delcath Systems Q1 Earnings Call Highlights

Delcath Systems (NASDAQ:DCTH) reported first-quarter 2026 revenue growth and reiterated its full-year outlook, while updating expectations for U.S. treatment-center activations and outlining progress across...

DCTH : 14.00 (+10.85%)

Business Summary

Delcath Systems, Inc. has developed a system, the Delcath system, to isolate the liver from the general circulatory system and to administer chemotherapy and other therapeutic agents directly to the liver.

See More

Key Turning Points

3rd Resistance Point 13.93
2nd Resistance Point 13.59
1st Resistance Point 13.11
Last Price 14.00
1st Support Level 12.29
2nd Support Level 11.95
3rd Support Level 11.47

See More

52-Week High 14.00
Last Price 14.00
Fibonacci 61.8% 11.75
Fibonacci 50% 11.06
Fibonacci 38.2% 10.37
52-Week Low 8.12

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.